Literature DB >> 34978674

A long-term survival case of Erdheim-Chester disease on maintenance hemodialysis.

Ryo Konishi1, Takuya Morinishi2, Koji Takaori2, Yuta Iwamoto2, Makiko Kondo2, Sayako Maeda2.   

Abstract

Erdheim-Chester disease, a rare non-Langerhans histiocytosis, involves multiple organs, including kidney. Renal dysfunction sometimes occurs, and is attributed to ureteral obstruction and renal artery stenosis by histiocytic infiltration. However, to our knowledge, case reports of end-stage renal disease requiring renal replacement therapy due to Erdheim-Chester disease are very few. Here, we report a 69-year-old woman who was diagnosed with Erdheim-Chester disease 10 years ago. She had multiple organ involvement, such as bone, skin, heart, pituitary gland, kidney, and retroperitoneum. She had been treated with interferon-alpha, but discontinued after 2 years due to depression and repeated infection. She did not desire treatment with other drugs, so we continued supportive care. Her renal function gradually deteriorated, and hemodialysis was initiated 4 years ago. Subsequently, she is still doing well without any major symptoms. This report describes an unusual case of Erdheim-Chester disease requiring maintenance hemodialysis that longer prognosis than expected was obtained regardless of multiple organ involvement and no specific treatment after interferon-alpha cessation.
© 2022. Japanese Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34978674      PMCID: PMC9343548          DOI: 10.1007/s13730-021-00680-0

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  14 in total

Review 1.  Erdheim-Chester disease as cause of end-stage renal failure: a case report and review of the literature.

Authors:  Jose Emilio Sanchez; Carmen Mora; Manuel Macia; Juan F Navarro
Journal:  Int Urol Nephrol       Date:  2010-03-16       Impact factor: 2.370

2.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Authors:  Julien Haroche; Frédéric Charlotte; Laurent Arnaud; Andreas von Deimling; Zofia Hélias-Rodzewicz; Baptiste Hervier; Fleur Cohen-Aubart; David Launay; Annette Lesot; Karima Mokhtari; Danielle Canioni; Louise Galmiche; Christian Rose; Marc Schmalzing; Sandra Croockewit; Marianne Kambouchner; Marie-Christine Copin; Sylvie Fraitag; Felix Sahm; Nicole Brousse; Zahir Amoura; Jean Donadieu; Jean-François Emile
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

3.  Image of Erdheim-Chester disease requiring hemodialysis.

Authors:  Maki Tsukamoto; Masaaki Akahane; Masaomi Nangaku
Journal:  Clin Exp Nephrol       Date:  2012-08-04       Impact factor: 2.801

Review 4.  Erdheim-Chester disease.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Zahir Amoura
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

5.  CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

Authors:  Laurent Arnaud; Baptiste Hervier; Antoine Néel; Mohamed A Hamidou; Jean-Emmanuel Kahn; Bertrand Wechsler; Gemma Pérez-Pastor; Bjørn Blomberg; Jean-Gabriel Fuzibet; François Dubourguet; António Marinho; Catherine Magnette; Violaine Noel; Michel Pavic; Jochen Casper; Anne-Bérangère Beucher; Nathalie Costedoat-Chalumeau; Laurent Aaron; Juan Salvatierra; Carlos Graux; Patrice Cacoub; Véronique Delcey; Claudia Dechant; Pascal Bindi; Christiane Herbaut; Giorgio Graziani; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

6.  Urologic manifestations of Erdheim-Chester disease.

Authors:  Daniel A Yelfimov; Deborah J Lightner; Matthew K Tollefson
Journal:  Urology       Date:  2014-04-27       Impact factor: 2.649

Review 7.  Multiple system Erdheim-Chester disease with massive hypothalamic-sellar involvement and hypopituitarism.

Authors:  Thaira Oweity; Bernd W Scheithauer; Hin San Ching; ChangMohC Lei; Koh Ping Wong
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

8.  Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Jean-François Emile; Laurent Arnaud; Philippe Maksud; Frédéric Charlotte; Philippe Cluzel; Aurélie Drier; Baptiste Hervier; Neïla Benameur; Sophie Besnard; Jean Donadieu; Zahir Amoura
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

9.  Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.

Authors:  Takashi Toya; Mizuki Ogura; Kazuhiro Toyama; Akihide Yoshimi; Aya Shinozaki-Ushiku; Akira Honda; Kenjiro Honda; Noriko Hosoya; Yukako Murakami; Hiroyuki Kawashima; Yasuhito Nannya; Shunya Arai; Fumihiko Nakamura; Yusuke Shinoda; Masaomi Nangaku; Kiyoshi Miyagawa; Masashi Fukayama; Akiko Moriya-Saito; Ichiro Katayama; Takashi Ogura; Mineo Kurokawa
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.